TrialDiabetes, obesity & metabolism2018

Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment (chronic kidney disease stage 3A): The DERIVE Study.

Paola Fioretto et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.